One-Swab Test Screens 19 Respiratory Pathogens
Labs can now run a single nasopharyngeal swab for up to 19 viral and bacterial targets, with results in under two hours.
Updated on Nov. 2, 2026 in COVID-19

The FDA granted 510(k) clearance to Roche's cobas eplex respiratory pathogen panel 3 (RP3), a single-swab test that detects up to 19 viral and bacterial targets, including SARS-CoV-2, influenza and Bordetella pertussis. Roche announced the clearance on November 2, 2026, and the test is aimed at laboratories that run respiratory testing.
Why it matters
A single nasopharyngeal swab that screens for many respiratory pathogens at once can help labs identify the likely cause of respiratory illness more efficiently, which matters during overlapping seasons of COVID-19, flu and other infections. The 510(k) pathway means the FDA judged the device substantially equivalent to a device already legally marketed.
The clearance rests on the FDA's 510(k) review, which compares the device to a legally marketed predicate rather than requiring a new clinical efficacy trial. The source does not report the study design, sample size or accuracy measurements behind the clearance.
The players
Roche
Roche is a global pharmaceutical and diagnostics company known for molecular diagnostic platforms, including the cobas line of testing systems.
U.S. Food and Drug Administration (FDA)
The FDA is the U.S. federal agency that regulates medical devices and diagnostics, including premarket clearance of tests like RP3.
The details
The RP3 test runs on Roche's cobas eplex system and uses one nasopharyngeal swab to check for up to 19 viral and bacterial targets, including Bordetella pertussis and updated assays for influenza and SARS-CoV-2. Laboratories can choose among as many as five panel configurations based on local disease prevalence and patient needs, a customization feature that requires cobas eplex software version 3.0 or higher. Hands-on preparation takes less than one minute and qualitative results arrive in under two hours.
Timeline
November 2, 2026: Roche announced FDA 510(k) clearance of the RP3 panel.
Health Landscape
Multiplex respiratory panels that test for several pathogens from one sample have expanded as clinicians manage overlapping seasonal infections. The RP3 clearance follows that trend by adding pertussis and updated influenza and SARS-CoV-2 assays to a single-swab workflow.
If you are tested for a respiratory illness, ask your clinician or lab whether a multiplex panel is being used, since one swab can screen for many possible causes at once. Availability will depend on individual laboratories choosing to adopt the RP3 panel.
The takeaway
A single swab that screens for many respiratory pathogens can speed up identifying the cause of illness. If you need testing, it is reasonable to ask your clinician which panel your lab uses.
Further reading
For more on how respiratory viruses are tracked and tested, see the COVID-19 coverage.
Source note: This article includes information reported by TokenPost.





